Kamada director Karnit Goldwasser awarded 30,000 stock options

What happened

Kamada Ltd. (KMDA), an Israeli pharmaceutical company, disclosed on Aug. 6, 2026, that director Karnit Goldwasser was granted 30,000 employee stock options on Aug. 5, 2026. The grant was reported on SEC Form 4, a document insiders must file when they buy or sell company stock or receive equity awards.

The filing shows the options have an exercise price of $7.52 per share, converted from Israeli shekels at the Bank of Israel's exchange rate on Aug. 4, 2026. The options vest in four equal annual installments over four years and remain exercisable for 10 years from the grant date.

According to the filing, the options are held by a trustee under Kamada's 2011 Share Award Plan. The filing does not state why the grant was made; it reports only the transaction details.

Kamada's stock closed at $8.24 on Aug. 6, up 2.74% from the prior close of $8.02. The filing does not explain the price move.

The filing

This is one of 9 insider transaction filings for Kamada over the past 14 days, according to the signal that flagged this event. The Aug. 6 filing is a single Form 4, submitted by Karnit Goldwasser, a director of the company.

A Form 4 is filed under Section 16(a) of the Securities Exchange Act of 1934. It is required whenever a company's officers, directors, or beneficial owners of more than 10% of a class of stock buy, sell, or receive equity securities. The form's purpose is to make insider activity public in near real-time.

The transaction code listed is 'A,' meaning an acquisition. In this case, the acquisition is an award of options, not a purchase of shares. The 'I' in the ownership form column indicates the options are held indirectly, through a trustee.

What this means

The filing shows Goldwasser received 30,000 employee stock options. Stock options are a type of derivative security that give the holder the right to buy a set number of shares at a fixed price—here $7.52 per share—for a specified period. Since the stock's current price of $8.24 is above the exercise price, the options are 'in the money,' meaning they could be exercised immediately for a paper gain, but they are subject to vesting.

The vesting schedule means Goldwasser cannot exercise all the options at once. 25% vest on each of the first four anniversaries of the grant date, so full exercise is possible only after four years. This is a common structure for employee equity awards, designed to encourage long-term commitment.

The options are held by a trustee under Kamada's 2011 Share Award Plan, which is the equity compensation plan the company uses to grant stock and options to directors and employees. The filing does not say whether the grant is a routine annual award, a new-hire incentive, or something else.

A cluster of 9 insider filings in 14 days can draw attention, but this particular filing is an acquisition, not a sale. The Form 4 itself does not explain the reason for the grant or the recent trading activity. Investors looking for context would need to review the other filings or company announcements.